Q-omics provides the consensus-scored RELL1 profile across patient tissues and cancer cell-line models. RELL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RELL1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RELL1 RNA expression shows 19,543 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, COAD, and THYM as cancer lineages where RELL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RELL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RELL1 survival associations across molecular data types. RELL1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RELL1 RNA expression–survival associations across cancer types. High RELL1 expression shows unfavorable associations in MESO, BLCA and LGG, but favorable associations in KIRC, ESCA and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for RELL1 RNA expression.
This table summarizes RELL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RELL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RELL1 shows lower tumor expression in COAD, THCA, LUAD and KICH and higher tumor expression in HNSC and KIRC. The COAD box plot shows higher RELL1 RNA expression in normal versus tumor tissue (log2 FC = −1.155, t-test p < 0.001).
This table shows molecular features associated with RELL1 in patient tissues and cancer cell lines. In patient samples, RELL1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RELL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
